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Available online 25 February 2011In an era where significant progress in endovascular tech-
nologies has drastically altered the treatment paradigm for
patients with femoro-popliteal occlusive disease and cath-
eter-based interventions have become the initial treatment
of choice in many patients with intermittent claudication or
critical limb ischemia (CLI), surgical revascularization of
the lower leg is performed less frequently but still remains
the reference for treatment due to demonstrated durability
and efficacy. This has been endorsed by the recent results
form the Scandinavian Propaten study, a large multicenter
randomized trial analyzing outcomes of PTFE grafts with
heparin bonded luminal surface compared to ordinary pure
PTFE grafts in patients with peripheral disease. After
randomizing 569 patients through eleven Scandinavian
centers, Lindholt et al. found that the use of heparin
bounded PTFE grafts was associated with a significant
decrease of primary graft failure by 37% at 1 year. Risk
reduction was particularly evident (50%) in the subgroups of
patients with CLI and with femoro-popliteal by-pass.1
The first lesson from this recent study is that surgery is
no more considered competitor of medical therapy. For
many vascular diseases medicine and surgery are today the
best companions to reach and optimize the same goals.
Vascular research for peripheral disease is rapidly moving
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doi:10.1016/j.ejvs.2011.02.009drugs, materials and technologies such as drug-eluting-
stents and drug-coated-balloons. Promising even though
preliminary results have been recently shown in patients
with CLI and above- or below-the-knee lesions with these
new approaches. Nevertheless, also longstanding and
established materials and drugs such as PTFE grafts and
heparin, when used together, can assist each other to
obtain the same improved goal in peripheral disease, as
shown by the Propaten study.
The second lesson from the study of Lindholt et al. is that
today the management of peripheral artery disease is still an
open issue where a true gold standard is lacking. As in many
other trials on peripheral diseases, the inclusion in the Prop-
aten population of CLI together with intermittens claudica-
tion, of femoroefemoro- crossover by-pass together with
femoro-popliteal by-pass, and of above-the-knee together
with below-the-knee revascularizations make the results of
this study less generalizable for real clinical settings where
treatment is usually individualized to more specific condi-
tions. Even though Lindholt et al. performed subgroup anal-
yses by clinical condition and by-pass type, their conclusions
regarding higher benefit of heparin bondedPTFE inCLI (1-year
patency 82.7% vs 70%) and femoro-popliteal by-pass (1-year
patency 80.4% vs 69.6%) subgroups should be accepted with
caution because these data lack the consistency of
a randomized study.
Finally, long-term durability of PTFE by-pass could not be
clarified in the Propaten trial where the heparin coat of the
graftswasexpected toprovideanearlybenefitonpatencyandd by Elsevier Ltd. All rights reserved.
Results from the Propaten Trial 675only 1-year results were tested. In addition, since regular
duplex surveillancewasnot performedevery threemonths for
lack of funds, all graft occlusions could be assessed with
imaging at the final 1-year evaluation. Therefore, uncertainty
remains regarding accurate time extent of the effect and the
benefit of heparin surface bonding over PTFE graft patency.
Lower limb revascularization still represents the most
ambiguous and challenging vascular field to be investi-
gated today. Due to the heterogeneity of disparate
factors affecting peripheral artery disease, performing
a well-randomized study is demanding and costly. It is
often impending to alternatively choose whether to be
more rigorous and selective in inclusion criteria and be
penalized by small recruitment numbers or to perform
a more general trial with a large population (as thePropaten trial) but be disadvantaged by weakened results
and high costs.
Despite inevitable limitations of studies like the Prop-
aten, the efficacy of old-fashioned procedures using medi-
cine and surgery partnership is an essential tool that cannot
be ignored in today’s management of peripheral diseases.
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